Biotech News
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
RASONQUE once-daily oral tablets indicated as a monotherapy for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy Approval includes patients with or without an identified RAS tumor mutation Revolution Medicines is
